Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Pantoprazole magnesium
All products: general benefit
Mylan-Pantoprazole T · DIN 02408570 · 40 mg · Ent Coated tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mylan-Pantoprazole T · DIN 02408570
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2015-10-29
Health Canada: Marketed since 2015-08-31 · brand MYLAN-PANTOPRAZOLE T · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM HEMIPENTAHYDRATE) 40 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMylan-Pantoprazole T: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1875). What the ministry pays, not the patient.
Ministry pays: $0.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02408570)
Source record
DIN 02408570: Mylan-Pantoprazole T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id MYL
Source form: Ent Coated Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1875; ministry $0.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02408570
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89331
Interchangeable products
Pantoprazole Magnesium · DIN 02441853 · $0.1875
Pantoprazole T · DIN 02466147 · $0.1875
Pantoprazole T · DIN 02519534 · $0.1875
Tecta · DIN 02267233 · $0.1875
Teva-Pantoprazole Magnesium · DIN 02440628 · $0.1875
Shortage status: active shortage (reported December 22, 2025, estimated to end January 12, 2027, last updated September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408570
Shortage record checked October 6, 2026
Pantoprazole T · DIN 02466147 · 40 mg · Ent Coated tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pantoprazole T · DIN 02466147
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2017-10-25 · brand PANTOPRAZOLE T · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM HEMIPENTAHYDRATE) 40 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPantoprazole T: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1875). What the ministry pays, not the patient.
Ministry pays: $0.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02466147)
Source record
DIN 02466147: Pantoprazole T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id SAI
Source form: Ent Coated Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1875; ministry $0.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02466147
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95445
Interchangeable products
Mylan-Pantoprazole T · DIN 02408570 · $0.1875
Pantoprazole Magnesium · DIN 02441853 · $0.1875
Pantoprazole T · DIN 02519534 · $0.1875
Tecta · DIN 02267233 · $0.1875
Teva-Pantoprazole Magnesium · DIN 02440628 · $0.1875
Shortage status: active shortage (reported December 8, 2025, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466147
Shortage record checked October 6, 2026
Pantoprazole T · DIN 02519534 · 40 mg · Ent Coated tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pantoprazole T · DIN 02519534
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-03-31
Health Canada: Marketed since 2023-02-07 · brand PANTOPRAZOLE MAGNESIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM HEMIPENTAHYDRATE) 40 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPantoprazole T: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1875). What the ministry pays, not the patient.
Ministry pays: $0.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519534)
Source record
DIN 02519534: Pantoprazole T
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id SIV
Source form: Ent Coated Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1875; ministry $0.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519534
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100878
Interchangeable products
Mylan-Pantoprazole T · DIN 02408570 · $0.1875
Pantoprazole Magnesium · DIN 02441853 · $0.1875
Pantoprazole T · DIN 02466147 · $0.1875
Tecta · DIN 02267233 · $0.1875
Teva-Pantoprazole Magnesium · DIN 02440628 · $0.1875
Shortage status: active shortage (reported June 1, 2026, estimated to end February 1, 2027, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519534
Shortage record checked October 6, 2026
Tecta · DIN 02267233 · 40 mg · Ent Coated tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Tecta (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Tecta · DIN 02267233
Manufacturer: Nycomed Canada Inc.; listing date 2010-06-14
Health Canada: Marketed since 2013-06-21 · brand TECTA · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) 40 MG · company Takeda canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02267233)
Source record
DIN 02267233: Tecta
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id NYC
Source form: Ent Coated Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.8260; ministry $0.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02267233
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75263
Interchangeable products
Mylan-Pantoprazole T · DIN 02408570 · $0.1875
Pantoprazole Magnesium · DIN 02441853 · $0.1875
Pantoprazole T · DIN 02466147 · $0.1875
Pantoprazole T · DIN 02519534 · $0.1875
Teva-Pantoprazole Magnesium · DIN 02440628 · $0.1875
Shortage status: shortage reported ended September 28, 2026 (report last updated September 28, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02267233
Shortage record checked October 6, 2026
Teva-Pantoprazole Magnesium · DIN 02440628 · 40 mg · Ent Coated tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Pantoprazole Magnesium · DIN 02440628
Manufacturer: Teva Canada Limited; listing date 2016-01-28
Health Canada: Marketed since 2015-11-16 · brand TEVA-PANTOPRAZOLE MAGNESIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) 40 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Pantoprazole Magnesium: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1875). What the ministry pays, not the patient.
Ministry pays: $0.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02440628)
Source record
DIN 02440628: Teva-Pantoprazole Magnesium
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id TEV
Source form: Ent Coated Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1875; ministry $0.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02440628
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92500
Interchangeable products
Mylan-Pantoprazole T · DIN 02408570 · $0.1875
Pantoprazole Magnesium · DIN 02441853 · $0.1875
Pantoprazole T · DIN 02466147 · $0.1875
Pantoprazole T · DIN 02519534 · $0.1875
Tecta · DIN 02267233 · $0.1875
Shortage status: active shortage (reported September 17, 2025, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02440628
Shortage record checked October 6, 2026
Pantoprazole Magnesium · DIN 02441853 · 40 mg · Ent Coated tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-24 — choose a marketed DIN from the same-category list.Discontinued April 24, 2026 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-24 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-04-24 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pantoprazole Magnesium · DIN 02441853
Manufacturer: Altius Healthcare Inc.; listing date 2015-11-26
Health Canada: Cancelled post market since 2026-04-24 · brand PANTOPRAZOLE MAGNESIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE MAGNESIUM) 40 MG · company Altius healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPantoprazole Magnesium: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1875). What the ministry pays, not the patient.
Ministry pays: $0.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02441853)
Source record
DIN 02441853: Pantoprazole Magnesium
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000108; group id 692; item number 1714; lccId None; manufacturer id ALH
Source form: Ent Coated Tab; strength: 40mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1875; ministry $0.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02441853
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92624
Interchangeable products
Mylan-Pantoprazole T · DIN 02408570 · $0.1875
Pantoprazole T · DIN 02466147 · $0.1875
Pantoprazole T · DIN 02519534 · $0.1875
Tecta · DIN 02267233 · $0.1875
Teva-Pantoprazole Magnesium · DIN 02440628 · $0.1875
Shortage status: resolved shortage (ended September 2, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441853
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 24, 2026 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (A02B, A02BC): coverage varies; not interchangeable
- Rabeprazole (Pariet): general benefit
- Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
- Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, not a benefit
- Dexlansoprazole (Dexilant): not a benefit
- Esomeprazole (Nexium DR Tab): not a benefit
- Cimetidine: general benefit, not a benefit
6 more in the class list below
Pantoprazole sodium
11 Limited Use · 7 not a benefit
AG-Pantoprazole Sodium · DIN 02481588 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Pantoprazole Sodium · DIN 02481588
Manufacturer: Angita Pharma Inc.; listing date 2021-01-29
Health Canada: Marketed since 2018-12-27 · brand AG-PANTOPRAZOLE SODIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Angita pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAG-Pantoprazole Sodium: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02481588)
Source record
DIN 02481588: AG-Pantoprazole Sodium
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id ANG
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02481588
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97204
Interchangeable products
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02481588
Shortage record checked October 6, 2026
Apo-Pantoprazole · DIN 02292920 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Pantoprazole · DIN 02292920
Manufacturer: Apotex Inc.; listing date 2008-05-16
Health Canada: Marketed since 2008-03-05 · brand APO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02292920)
Source record
DIN 02292920: Apo-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id APX
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02292920
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77827
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: active shortage (reported September 22, 2026, estimated to end October 9, 2026, last updated September 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02292920
Shortage record checked October 6, 2026
Auro-Pantoprazole · DIN 02415208 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Pantoprazole · DIN 02415208
Manufacturer: Auro Pharma Inc.; listing date 2014-05-29
Health Canada: Marketed since 2016-02-06 · brand AURO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02415208)
Source record
DIN 02415208: Auro-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id AUR
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02415208
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89982
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended September 5, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02415208
Shortage record checked October 6, 2026
Bio-Pantoprazole · DIN 02445867 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Pantoprazole · DIN 02445867
Manufacturer: Biomed Pharma; listing date 2026-07-31
Health Canada: Marketed since 2024-03-13 · brand BIO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02445867)
Source record
DIN 02445867: Bio-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id BMP
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02445867
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93114
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended November 27, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02445867
Shortage record checked October 6, 2026
Jamp Pantoprazole Sodium · DIN 02392623 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Pantoprazole Sodium · DIN 02392623
Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30
Health Canada: Marketed since 2021-03-18 · brand JAMP PANTOPRAZOLE SODIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Pantoprazole Sodium: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02392623)
Source record
DIN 02392623: Jamp Pantoprazole Sodium
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id JPC
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02392623
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87788
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended May 2, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02392623
Shortage record checked October 6, 2026
Jamp-Pantoprazole · DIN 02357054 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Pantoprazole · DIN 02357054
Manufacturer: Jamp Pharma Corporation; listing date 2014-02-27
Health Canada: Marketed since 2020-06-15 · brand JAMP-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357054)
Source record
DIN 02357054: Jamp-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id JPC
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357054
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84215
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357054
Shortage record checked October 6, 2026
M-Pantoprazole · DIN 02467372 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Pantoprazole · DIN 02467372
Manufacturer: Mantra Pharma Inc.; listing date 2019-03-28
Health Canada: Marketed since 2024-08-21 · brand M-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02467372)
Source record
DIN 02467372: M-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id MAT
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02467372
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95575
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended September 15, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467372
Shortage record checked October 6, 2026
Mar-Pantoprazole · DIN 02416565 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Pantoprazole · DIN 02416565
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-04-01
Health Canada: Marketed since 2014-07-18 · brand MAR-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416565)
Source record
DIN 02416565: Mar-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id MAR
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416565
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90116
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended June 16, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416565
Shortage record checked October 6, 2026
Mint-Pantoprazole · DIN 02417448 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Pantoprazole · DIN 02417448
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-04-30
Health Canada: Marketed since 2014-01-16 · brand MINT-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02417448)
Source record
DIN 02417448: Mint-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id MIN
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02417448
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90206
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended November 14, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02417448
Shortage record checked October 6, 2026
NRA-Pantoprazole · DIN 02471825 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Pantoprazole · DIN 02471825
Manufacturer: Nora Pharma; listing date 2020-10-30
Health Canada: Marketed since 2024-05-27 · brand NRA-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471825)
Source record
DIN 02471825: NRA-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id NRA
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471825
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96103
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
PMS-Pantoprazole · DIN 02307871 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471825
Shortage record checked October 6, 2026
PMS-Pantoprazole · DIN 02307871 · 40 mg · enteric-coated tablet
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Pantoprazole · DIN 02307871
Manufacturer: Pharmascience Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-06-04 · brand PMS-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Pantoprazole: Formulary list price $0.20 per unit (the source does not state the unit; exact figure $0.2016). What the ministry pays, not the patient.
Ministry pays: $0.2016 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02307871)
Source record
DIN 02307871: PMS-Pantoprazole
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000080; group id 694; item number 1716; lccId 00106; manufacturer id PMS
Source form: Ent Tab; strength: 40mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2016; ministry $0.2016
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02307871
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79355
Interchangeable products
AG-Pantoprazole Sodium · DIN 02481588 · $0.2016
Apo-Pantoprazole · DIN 02292920 · $0.2016
Auro-Pantoprazole · DIN 02415208 · $0.2016
Bio-Pantoprazole · DIN 02445867 · $0.2016
Co Pantoprazole · DIN 02300486 · $0.2016
Jamp Pantoprazole Sodium · DIN 02392623 · $0.2016
Jamp-Pantoprazole · DIN 02357054 · $0.2016
M-Pantoprazole · DIN 02467372 · $0.2016
Mar-Pantoprazole · DIN 02416565 · $0.2016
Mint-Pantoprazole · DIN 02417448 · $0.2016
NRA-Pantoprazole · DIN 02471825 · $0.2016
Pantoloc · DIN 02229453 · $0.2016
Pantoprazole · DIN 02370808 · $0.2016
Pantoprazole · DIN 02428180 · $0.2016
Pantoprazole · DIN 02431327 · $0.2016
Pantoprazole · DIN 02547368 · $0.2016
Ran-Pantoprazole · DIN 02305046 · $0.2016
Sandoz Pantoprazole · DIN 02301083 · $0.2016
Teva-Pantoprazole · DIN 02285487 · $0.2016
Shortage status: resolved shortage (ended June 9, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02307871
Shortage record checked October 6, 2026
Apo-Pantoprazole · DIN 02292912 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Pantoprazole · DIN 02292912
Manufacturer: Apotex Inc.; listing date 2008-06-27
Health Canada: Marketed since 2008-03-05 · brand APO-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02292912)
Source record
DIN 02292912: Apo-Pantoprazole
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id APX
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02292912
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77826
Interchangeable products
Jamp Pantoprazole Sodium · DIN 02392615 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoloc · DIN 02241804 · not recorded
Pantoprazole · DIN 02428172 · not recorded
Pantoprazole · DIN 02536137 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Sandoz Pantoprazole · DIN 02301075 · not recorded
Teva-Pantoprazole · DIN 02285479 · not recorded
Shortage status: resolved shortage (ended February 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02292912
Shortage record checked October 6, 2026
Jamp Pantoprazole Sodium · DIN 02392615 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Pantoprazole Sodium · DIN 02392615
Manufacturer: Jamp Pharma Corporation; listing date 2021-11-30
Health Canada: Marketed since 2021-11-26 · brand JAMP PANTOPRAZOLE SODIUM · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02392615)
Source record
DIN 02392615: Jamp Pantoprazole Sodium
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id JPC
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02392615
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87787
Interchangeable products
Apo-Pantoprazole · DIN 02292912 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoloc · DIN 02241804 · not recorded
Pantoprazole · DIN 02428172 · not recorded
Pantoprazole · DIN 02536137 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Sandoz Pantoprazole · DIN 02301075 · not recorded
Teva-Pantoprazole · DIN 02285479 · not recorded
Shortage status: resolved shortage (ended August 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02392615
Shortage record checked October 6, 2026
Pantoloc · DIN 02241804 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Pantoloc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Pantoloc · DIN 02241804
Manufacturer: Nycomed Canada Inc.; listing date 2008-06-27
Health Canada: Marketed since 2013-01-09 · brand PANTOLOC · ATC A02BC02 PANTOPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Takeda canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPantoloc: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02241804)
Source record
DIN 02241804: Pantoloc
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id NYC
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241804
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65469
Interchangeable products
Apo-Pantoprazole · DIN 02292912 · not recorded
Jamp Pantoprazole Sodium · DIN 02392615 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoprazole · DIN 02428172 · not recorded
Pantoprazole · DIN 02536137 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Sandoz Pantoprazole · DIN 02301075 · not recorded
Teva-Pantoprazole · DIN 02285479 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241804
Shortage record checked October 6, 2026
Pantoprazole · DIN 02428172 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Pantoprazole · DIN 02428172
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2024-03-21 · brand PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02428172)
Source record
DIN 02428172: Pantoprazole
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id SIV
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02428172
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91265
Interchangeable products
Apo-Pantoprazole · DIN 02292912 · not recorded
Jamp Pantoprazole Sodium · DIN 02392615 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoloc · DIN 02241804 · not recorded
Pantoprazole · DIN 02536137 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Sandoz Pantoprazole · DIN 02301075 · not recorded
Teva-Pantoprazole · DIN 02285479 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02428172
Shortage record checked October 6, 2026
Pantoprazole · DIN 02536137 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Pantoprazole · DIN 02536137
Manufacturer: Sanis Health Inc.; listing date 2024-01-31
Health Canada: Marketed since 2023-11-17 · brand PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536137)
Source record
DIN 02536137: Pantoprazole
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id SAI
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536137
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102493
Interchangeable products
Apo-Pantoprazole · DIN 02292912 · not recorded
Jamp Pantoprazole Sodium · DIN 02392615 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoloc · DIN 02241804 · not recorded
Pantoprazole · DIN 02428172 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Sandoz Pantoprazole · DIN 02301075 · not recorded
Teva-Pantoprazole · DIN 02285479 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536137
Shortage record checked October 6, 2026
Sandoz Pantoprazole · DIN 02301075 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Pantoprazole · DIN 02301075
Manufacturer: Sandoz Canada Inc.; listing date 2008-11-04
Health Canada: Marketed since 2008-06-03 · brand SANDOZ PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02301075)
Source record
DIN 02301075: Sandoz Pantoprazole
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id SDZ
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02301075
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78642
Interchangeable products
Apo-Pantoprazole · DIN 02292912 · not recorded
Jamp Pantoprazole Sodium · DIN 02392615 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoloc · DIN 02241804 · not recorded
Pantoprazole · DIN 02428172 · not recorded
Pantoprazole · DIN 02536137 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Teva-Pantoprazole · DIN 02285479 · not recorded
Shortage status: resolved shortage (ended June 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02301075
Shortage record checked October 6, 2026
Teva-Pantoprazole · DIN 02285479 · 20 mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Pantoprazole · DIN 02285479
Manufacturer: Teva Canada Limited; listing date 2008-08-28
Health Canada: Marketed since 2023-03-22 · brand TEVA-PANTOPRAZOLE · ATC A02BC02 PANTOPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 20 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02285479)
Source record
DIN 02285479: Teva-Pantoprazole
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 564000106; group id 693; item number 1715; lccId None; manufacturer id TEV
Source form: Ent Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.2750; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285479
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77096
Interchangeable products
Apo-Pantoprazole · DIN 02292912 · not recorded
Jamp Pantoprazole Sodium · DIN 02392615 · not recorded
Jamp-Pantoprazole · DIN 02408414 · not recorded
Mar-Pantoprazole · DIN 02416557 · not recorded
Pantoloc · DIN 02241804 · not recorded
Pantoprazole · DIN 02428172 · not recorded
Pantoprazole · DIN 02536137 · not recorded
Ran-Pantoprazole · DIN 02305038 · not recorded
Sandoz Pantoprazole · DIN 02301075 · not recorded
Shortage status: active shortage (reported March 6, 2024, last updated March 7, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285479
Shortage record checked October 6, 2026
Other products in the same Health Canada class (A02B, A02BC): coverage varies; not interchangeable
- Rabeprazole (Pariet): general benefit
- Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
- Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, not a benefit
- Dexlansoprazole (Dexilant): not a benefit
- Esomeprazole (Nexium DR Tab): not a benefit
- Cimetidine: general benefit, not a benefit
6 more in the class list below
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered
Matched class: 56:40 Miscellaneous G.I. Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, RABEPRAZOLE SODIUM, SUCRALFATE
Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL
56:40 Miscellaneous G.I. Drugs
· 16 products · General benefit · strengths: 10mg, 20mg · Tab
· 16 products ·
Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap
· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2),
Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap
· 22 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 20mg · DR Tab
· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab
· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab
· 2 products · General benefit · strengths: 150mg, 300mg · Cap
· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab
· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab
· 2 products · Listed, not a benefit (1),
Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40
and 9 more
Full class listing
Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Availability
Mylan-Pantoprazole T · DIN 02408570
Shortage status: active shortage (reported 2025-12-22, estimated to end 2027-01-12, last updated 2026-09-03); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02408570
Check this DIN againPantoprazole T · DIN 02466147
Shortage status: active shortage (reported 2025-12-08, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466147
Check this DIN againPantoprazole T · DIN 02519534
Shortage status: active shortage (reported 2026-06-01, estimated to end 2027-02-01, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519534
Check this DIN againTecta · DIN 02267233
Shortage status: shortage reported ended 2026-09-28 (report last updated 2026-09-28); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02267233
Check this DIN againTeva-Pantoprazole Magnesium · DIN 02440628
Shortage status: active shortage (reported 2025-09-17, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02440628
Check this DIN againApo-Pantoprazole · DIN 02292920
Shortage status: active shortage (reported 2026-09-22, estimated to end 2026-10-09, last updated 2026-09-25); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02292920
Check this DIN againTeva-Pantoprazole · DIN 02285479
Shortage status: active shortage (reported 2024-03-06, last updated 2024-03-07) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285479
Check this DIN again